Top Tamoxifen Brands for Effective Breast Cancer Treatment

Tamoxifen, a commonly used medication for breast cancer treatment and prevention, is available under various brand names around the world. Known for its effectiveness, it is essential to choose a brand that is trusted and highly recommended within the medical community. Popular brands often ensure superior quality and include Nolvadex, Soltamox, and Tamifen, each offering reliable formulations. For those interested in exploring these options further, a detailed list and analysis of the best Tamoxifen brands can be found below.

Illustration of tamoxifen

Best brands of tamoxifen in 2025

Nolvadex

Nolvadex, a brand name for tamoxifen citrate, is a leading medication in the treatment and prevention of breast cancer, particularly for hormone-receptor-positive cases. It has been shown to reduce the risk of breast cancer recurrence by 47% and mortality by 26% over a 5-year treatment period. Tamoxifen, available in 10 mg and 20 mg tablets, achieves steady-state plasma concentrations in about 4 weeks for tamoxifen and 8 weeks for its metabolite N-desmethyl tamoxifen. The drug has been widely used since its introduction, with production increasing significantly over the years, from 7 tonnes in 1989 to 103 tonnes in 1995. Nolvadex is also known for its role in reducing the incidence of contralateral breast cancer by up to 40% in some studies. For detailed information on Nolvadex, you can refer to the FDA-approved labeling document.

Soltamox

Soltamox, produced by Savient Pharmaceuticals, is a renowned brand for tamoxifen, specifically formulated as an oral liquid solution. It was first approved by the FDA on October 29, 2005, and is indicated for the treatment of estrogen receptor-positive breast cancer, including metastatic and early-stage cases, as well as for reducing the risk of invasive breast cancer in high-risk women. Clinical trials have shown that tamoxifen can reduce the incidence of contralateral breast cancer by up to 47% and invasive breast cancer by 44% in certain patient groups. Soltamox is available in a 20mg dose per 10mL solution and is known for its antiestrogenic properties. It is crucial to discuss the risks and benefits, including potential uterine malignancies and thromboembolic events, with patients. For more detailed information, visit the official Soltamox website.

Teva

Teva Pharmaceutical Industries Ltd is a leading producer of tamoxifen, known for its high-quality and effective generic version of the drug. Teva received final FDA approval for Tamoxifen Citrate 10mg Tablets in 2000, marking a significant milestone in the treatment of metastatic breast cancer and the reduction of breast cancer incidence in high-risk women. The company's product has been well-received, with many patients reporting fewer side effects compared to other brands, such as Mylan. Teva's dominance in the market is evident, as the North America tamoxifen market, where Teva is a key player, holds a significant share due to high acceptance and pricing of the drug. The global tamoxifen market, which includes Teva as a major player, was valued at USD 651.8 Million in 2023 and is expected to grow at a CAGR of 1% between 2024 and 2032.

Mylan

Mylan N.V. is a prominent player in the global tamoxifen market, known for its high-quality and widely accepted tamoxifen formulations. The company's products are particularly popular in North America, where the tamoxifen market is dominated due to high acceptance and pricing, with 30 tablets of 20mg tamoxifen costing around $65.71 on average in 2018. Mylan's involvement significantly contributes to the market's overall growth, with the breast cancer treatment segment capturing over 40% of the market share in 2023. The company's products are available in various formulations, with tablets being the leading segment, holding over 38% of the market share in value in 2023. Mylan's commitment to research and development further enhances its position in the tamoxifen market.

Actavis

Actavis, a renowned pharmaceutical company, is recognized for its high-quality production of tamoxifen, a selective estrogen receptor modulator crucial in treating and preventing breast cancer. The efficacy of Actavis's tamoxifen is supported by clinical trials showing significant reductions in breast cancer recurrence and mortality, with a 47% reduction in recurrence and a 26% reduction in mortality over 5 years of treatment. The company's commitment to precision and safety is reflected in the strict pharmacokinetic profiles of their tamoxifen products, achieving steady-state plasma concentrations of 122 ng/mL for tamoxifen and 353 ng/mL for its metabolite N-desmethyl tamoxifen after 3 months of daily administration. Actavis's tamoxifen is particularly valued in North America, where the drug market is dominated by high demand due to the high prevalence of breast cancer, with approximately 1 in 8 U.S. women estimated to develop invasive breast cancer in their lifetime. The company's product is priced competitively, with 30 tablets of 20mg tamoxifen costing around $65.71 on average, as per 2018 pricing details.

Sandoz

Sandoz, a renowned pharmaceutical company, is a significant producer of tamoxifen, a selective estrogen receptor modulator widely used in the treatment of estrogen receptor-positive breast cancer. Tamoxifen, produced by Sandoz, has been a cornerstone in breast cancer therapy, with its market valued at US$ 676.6 million in 2017 and predicted to grow to US$ 687.44 million by 2032, albeit at a low CAGR of 0.07%. The drug is registered for use in 97 countries and is a therapy of choice for premenopausal women, highlighting its global impact and clinical significance. Sandoz's production ensures high-quality tamoxifen citrate, which has seen increased global production over the years, from approximately 7.0 tonnes in 1989 to 103 tonnes in 1995. This consistent production and quality have solidified Sandoz's position as a reliable manufacturer in the tamoxifen market.

Zydus

Zydus, a renowned pharmaceutical company, is recognized as one of the leading producers of tamoxifen, a selective estrogen receptor modulator used to treat and prevent breast cancer. The company's commitment to quality and efficacy has made its tamoxifen products a preferred choice in the market. For instance, the global tamoxifen market, which includes contributions from Zydus, was valued at US$ 676.6 million in 2017 and is projected to grow to US$ 687.44 million by 2032, with a CAGR of 0.07%. Zydus's tamoxifen formulations are known for their high bioavailability and extensive protein binding, ensuring effective treatment outcomes. The company's strong presence in regions like North America and Asia-Pacific further solidifies its position in the tamoxifen market.

Wockhardt

Wockhardt is a notable producer of tamoxifen, a selective estrogen receptor modulator, which is crucial for treating estrogen receptor-positive breast cancer. Despite some users experiencing side effects like hot flushes and vaginal dryness, Wockhardt's tamoxifen has been a staple in many treatment regimens. However, manufacturing issues, such as those affected by Brexit, have led to supply disruptions and brand switches for some patients. The global tamoxifen market, including Wockhardt's offerings, is expected to grow at a CAGR of 0.07% by 2032, driven by increasing cancer prevalence and healthcare expenditure. North America, where Wockhardt's tamoxifen is widely used, dominates the market due to high acceptance and healthcare spending. For more in-depth analysis, you can explore the tamoxifen market report.

Apotex

Apotex Inc. is a prominent player in the tamoxifen market, known for its high-quality generic formulations. As a generic molecule, tamoxifen's market growth has been influenced by increased competition, but Apotex's strategic focus on combination therapies and additional therapeutic indications has helped maintain market presence. For instance, the emergence of combination therapies like Kisqali with tamoxifen has shown significant prolonged-free survival benefits, as seen in the MONALEESA-7 trials. Despite the challenges posed by the high cost of medication, which increased 10 times between 2011 and 2016, Apotex continues to be a key supplier, particularly with its competitive pricing in regions like India. The company's contributions to the market are further bolstered by increasing government and non-government investments in discovering new therapeutic applications for tamoxifen.

Accord

Accord, a prominent pharmaceutical company, is recognized for its high-quality production of tamoxifen, a selective estrogen receptor modulator. In 2020, tamoxifen was the 317th most commonly prescribed medication in the United States, with over 900,000 prescriptions, highlighting its widespread use and trust in the market. Accord's tamoxifen is part of a market expected to grow, with the global tamoxifen market projected to reach USD 1.8 billion by 2031, growing at a 4.5% CAGR from 2024 to 2031. The company's commitment to producing generic tamoxifen has enhanced pricing and accessibility, contributing to market expansion. With its strong presence in regions like North America and Europe, Accord continues to be a reliable producer of this essential medication.